Cough clinical trials at UCSF

1 research study open to eligible people

Efficacy and Safety Study of Orvepitant for Chronic Cough in Patients With Idiopathic Pulmonary Fibrosis
open to eligible people ages 40 years and up
ORV-PF-01 is a two way, placebo controlled, cross-over study, to evaluate the effect of two doses of orvepitant on cough in patients with IPF.
San Francisco, California and other locations

Last updated: March 20, 2023